| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 11 | 2020 | 638 | 1.560 |
Why?
|
| Breast Neoplasms | 10 | 2021 | 765 | 1.520 |
Why?
|
| Neoplastic Stem Cells | 7 | 2019 | 99 | 1.310 |
Why?
|
| Signal Transduction | 9 | 2018 | 682 | 1.180 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 1.170 |
Why?
|
| Cell Proliferation | 9 | 2019 | 604 | 1.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2015 | 105 | 1.030 |
Why?
|
| Receptors, Notch | 4 | 2018 | 16 | 1.010 |
Why?
|
| Membrane Proteins | 6 | 2015 | 256 | 0.970 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2008 | 36 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 261 | 0.810 |
Why?
|
| Microglia | 2 | 2020 | 57 | 0.780 |
Why?
|
| Calcium-Binding Proteins | 5 | 2015 | 45 | 0.710 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 220 | 0.680 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 111 | 0.680 |
Why?
|
| Mice | 17 | 2021 | 2484 | 0.640 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 31 | 0.620 |
Why?
|
| MicroRNAs | 2 | 2018 | 180 | 0.620 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 726 | 0.620 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.600 |
Why?
|
| Lysophosphatidylcholines | 2 | 2008 | 3 | 0.590 |
Why?
|
| Promoter Regions, Genetic | 4 | 2019 | 208 | 0.550 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2016 | 2 | 0.530 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 8 | 0.530 |
Why?
|
| Astrocytes | 3 | 2019 | 58 | 0.530 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 190 | 0.520 |
Why?
|
| Apoptosis | 2 | 2016 | 360 | 0.510 |
Why?
|
| DNA | 3 | 2019 | 226 | 0.500 |
Why?
|
| Animals | 20 | 2021 | 7542 | 0.450 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2009 | 18 | 0.410 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 414 | 0.400 |
Why?
|
| Dendritic Cells | 2 | 2009 | 59 | 0.390 |
Why?
|
| Radiosurgery | 3 | 2020 | 356 | 0.390 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 41 | 0.380 |
Why?
|
| Mice, Nude | 5 | 2020 | 291 | 0.370 |
Why?
|
| Transcription Factor AP-1 | 2 | 2008 | 19 | 0.350 |
Why?
|
| Humans | 26 | 2021 | 32114 | 0.330 |
Why?
|
| Microscopy, Atomic Force | 1 | 2008 | 5 | 0.320 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 14 | 0.320 |
Why?
|
| Neoplasms | 1 | 2016 | 728 | 0.310 |
Why?
|
| Cell Cycle | 2 | 2008 | 77 | 0.310 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 147 | 0.310 |
Why?
|
| Nicotine | 2 | 2021 | 174 | 0.310 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2011 | 36 | 0.300 |
Why?
|
| Proteins | 1 | 2009 | 144 | 0.300 |
Why?
|
| Lymphocytes | 1 | 2008 | 57 | 0.300 |
Why?
|
| Cell Differentiation | 2 | 2015 | 469 | 0.290 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 88 | 0.290 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 247 | 0.290 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2006 | 80 | 0.280 |
Why?
|
| Response Elements | 1 | 2006 | 16 | 0.280 |
Why?
|
| Female | 15 | 2021 | 20015 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 82 | 0.260 |
Why?
|
| Fluorescent Dyes | 2 | 2020 | 48 | 0.260 |
Why?
|
| Cells, Cultured | 6 | 2012 | 834 | 0.240 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2016 | 46 | 0.230 |
Why?
|
| Up-Regulation | 2 | 2018 | 189 | 0.220 |
Why?
|
| Blotting, Western | 5 | 2015 | 289 | 0.220 |
Why?
|
| Down-Regulation | 2 | 2018 | 142 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 4 | 2020 | 167 | 0.220 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 608 | 0.210 |
Why?
|
| NIH 3T3 Cells | 3 | 2013 | 43 | 0.190 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2018 | 9 | 0.190 |
Why?
|
| Perylene | 1 | 2020 | 1 | 0.180 |
Why?
|
| Tacrine | 1 | 2020 | 1 | 0.180 |
Why?
|
| Diazinon | 1 | 2020 | 3 | 0.180 |
Why?
|
| Cytokines | 2 | 2015 | 256 | 0.180 |
Why?
|
| Acetylcholinesterase | 1 | 2020 | 18 | 0.180 |
Why?
|
| Enzyme Activation | 3 | 2020 | 135 | 0.180 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2020 | 31 | 0.180 |
Why?
|
| Neutrophils | 1 | 2021 | 106 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2020 | 75 | 0.170 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Phosphorylation | 2 | 2011 | 229 | 0.170 |
Why?
|
| Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
| Connexins | 1 | 2019 | 3 | 0.170 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2019 | 5 | 0.170 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.160 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
| Electrochemical Techniques | 1 | 2019 | 23 | 0.160 |
Why?
|
| Nucleic Acid Conformation | 1 | 2019 | 48 | 0.160 |
Why?
|
| Lung | 1 | 2021 | 249 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 45 | 0.160 |
Why?
|
| Biosensing Techniques | 1 | 2019 | 25 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 100 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2019 | 181 | 0.160 |
Why?
|
| Protein Binding | 2 | 2009 | 201 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 60 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 101 | 0.150 |
Why?
|
| Calcium | 1 | 2019 | 307 | 0.140 |
Why?
|
| Medicare | 1 | 2018 | 206 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 155 | 0.140 |
Why?
|
| Stilbenes | 1 | 2016 | 23 | 0.140 |
Why?
|
| Cell Adhesion | 1 | 2016 | 108 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 148 | 0.130 |
Why?
|
| Mice, SCID | 2 | 2013 | 71 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 21 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2016 | 57 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 99 | 0.130 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 51 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 70 | 0.130 |
Why?
|
| Transfection | 2 | 2013 | 191 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 322 | 0.130 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2015 | 7 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 48 | 0.120 |
Why?
|
| Culture Media, Conditioned | 2 | 2013 | 51 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 471 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 25 | 0.110 |
Why?
|
| Anisomycin | 1 | 2013 | 3 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 16 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 42 | 0.110 |
Why?
|
| Cell Communication | 1 | 2013 | 32 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2013 | 50 | 0.110 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 27 | 0.110 |
Why?
|
| RNA Interference | 1 | 2013 | 76 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 115 | 0.110 |
Why?
|
| Inflammation | 1 | 2016 | 530 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2012 | 18 | 0.100 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2011 | 18 | 0.100 |
Why?
|
| beta Catenin | 1 | 2012 | 37 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 2 | 0.100 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 4 | 0.100 |
Why?
|
| Male | 8 | 2020 | 19217 | 0.100 |
Why?
|
| Cadherins | 1 | 2011 | 26 | 0.100 |
Why?
|
| Brain | 1 | 2018 | 951 | 0.090 |
Why?
|
| Prognosis | 3 | 2020 | 1497 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 495 | 0.090 |
Why?
|
| Rats | 2 | 2013 | 1596 | 0.090 |
Why?
|
| Time Factors | 2 | 2013 | 2151 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2011 | 84 | 0.090 |
Why?
|
| Cell Survival | 1 | 2011 | 285 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 324 | 0.090 |
Why?
|
| Genes, Reporter | 2 | 2006 | 40 | 0.090 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2009 | 12 | 0.080 |
Why?
|
| Infrared Rays | 1 | 2009 | 18 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 263 | 0.080 |
Why?
|
| Transplantation, Heterologous | 3 | 2015 | 122 | 0.080 |
Why?
|
| Binding Sites | 1 | 2009 | 130 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2009 | 39 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 767 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 3 | 0.080 |
Why?
|
| DNA Probes | 1 | 2008 | 19 | 0.080 |
Why?
|
| Flavonoids | 1 | 2008 | 18 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 42 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 88 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 37 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 71 | 0.080 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2008 | 2 | 0.080 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 75 | 0.080 |
Why?
|
| Pyridines | 1 | 2008 | 76 | 0.080 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2008 | 4 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2008 | 9 | 0.080 |
Why?
|
| Lectins, C-Type | 1 | 2008 | 13 | 0.080 |
Why?
|
| Imidazoles | 1 | 2008 | 91 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 123 | 0.080 |
Why?
|
| Triglycerides | 1 | 2008 | 230 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 166 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2008 | 103 | 0.070 |
Why?
|
| Cell Line | 1 | 2008 | 435 | 0.070 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 2006 | 1 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3510 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2006 | 14 | 0.070 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 26 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2006 | 33 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 594 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 85 | 0.070 |
Why?
|
| Intercalating Agents | 1 | 2005 | 9 | 0.060 |
Why?
|
| Organometallic Compounds | 1 | 2005 | 23 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1022 | 0.060 |
Why?
|
| Saponins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Panax notoginseng | 1 | 2004 | 1 | 0.060 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2004 | 4 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 11839 | 0.060 |
Why?
|
| Mutation | 1 | 2006 | 489 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 73 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2013 | 9 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 73 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 55 | 0.050 |
Why?
|
| Aged | 3 | 2019 | 10314 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2021 | 13 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2015 | 247 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 25 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 6 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2020 | 33 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 21 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 25 | 0.050 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2020 | 27 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2020 | 87 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 62 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 84 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 26 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 321 | 0.040 |
Why?
|
| DNA, Catalytic | 1 | 2019 | 4 | 0.040 |
Why?
|
| Chalcone | 1 | 2019 | 3 | 0.040 |
Why?
|
| Aptamers, Nucleotide | 1 | 2019 | 10 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2019 | 65 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 166 | 0.040 |
Why?
|
| Nanostructures | 1 | 2019 | 19 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 61 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 21 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 26 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 93 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2018 | 134 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 538 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 447 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 560 | 0.040 |
Why?
|
| Models, Biological | 1 | 2019 | 392 | 0.040 |
Why?
|
| Smoking | 1 | 2021 | 528 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 877 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 9380 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 308 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2015 | 3 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 23 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 48 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 160 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 483 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2265 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 2283 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2013 | 2 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 29 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 82 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 185 | 0.030 |
Why?
|
| Genes, myc | 1 | 2012 | 5 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 3 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 633 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3306 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 3990 | 0.020 |
Why?
|
| United States | 1 | 2018 | 3976 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2009 | 22 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 30 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2009 | 30 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2009 | 28 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 29 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 57 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 64 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 153 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 210 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 22 | 0.020 |
Why?
|
| Quinolines | 1 | 2005 | 21 | 0.020 |
Why?
|
| Cattle | 1 | 2005 | 103 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 58 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 171 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2004 | 6 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2004 | 11 | 0.020 |
Why?
|
| Luciferases | 1 | 2004 | 32 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2004 | 81 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 137 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 157 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 268 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 126 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2004 | 189 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 743 | 0.010 |
Why?
|